JANX
HealthcareJanux Therapeutics, Inc.
$13.75
+$0.10 (+0.73%)
Jan 5, 2026
Price History (1Y)
Analysis
Janux Therapeutics, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $827.03 million and 109 employees. The company operates within the biotechnology industry. Financially, Janux Therapeutics has reported a revenue of $10.00 million for the trailing twelve months (TTM), while its net income for the same period stands at -$101,895,000. The company's gross margin is 0.0%, operating margin is -352.5%, and profit margin is 0.0%. In terms of returns, Janux Therapeutics has a return on equity (ROE) of -12.5% and a return on assets (ROA) of -10.5%. The company's balance sheet reveals $22.66 million in debt and $988.99 million in cash. Janux Therapeutics' valuation context is characterized by a negative forward price-to-earnings (P/E) ratio of 4.62, a price-to-book ratio of 0.85, and a price-to-sales ratio of 82.70. The company's revenue growth for the year-over-year (YoY) period stands at 2177.9%, although earnings growth is not provided due to it being N/A.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $827.03M
- P/E Ratio
- N/A
- 52-Week High
- $61.59
- 52-Week Low
- $13.28
- Avg Volume
- 1.90M
- Beta
- 2.88
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 109